Researchers uncover new molecular drivers of Parkinson’s disease
Parkinson's is a neurodegenerative disease affecting the dopamine producing neurons in the substantia nigra of the brain. Credit: CC BY 3.0 - Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of Medicine 1 (2)
Scientists at the Icahn School of Medicine at Mount Sinai have uncovered new molecular drivers of Parkinson’s disease using a sophisticated statistical technique called multiscale gene network analysis (MGNA). The team was also able to determine how these molecular drivers impact the functions of genes involved in the disease. The results, which may point to potential new treatments, were published today in Nature Communications.
Some cases of Parkinson’s are directly caused by genetic mutations, but these cases are rare. Approximately 80 percent of cases have no known cause, and though there are some genes that may slightly increase an individual’s risk of developing the disease, the biological impacts of these genes remain unclear.
“This study offers a novel approach to understanding the majority of cases of Parkinson’s,” said Bin Zhang, PhD, Professor of Genetics and Genomic Sciences at the Icahn Institute for Data Science and Genomic Technology and Director of the Mount Sinai Center for Transformative Disease Modeling at the Icahn School of Medicine at Mount Sinai. “The strategy not only reveals new drivers, but it also elucidates the functional context of the known Parkinson’s disease risk factor genes.”
Dr. Zhang and his team originally developed the MGNA method to research the molecular mechanisms of Alzheimer’s disease. Since that study was published about six years ago, they have significantly improved the technique through funding from the National Institutes of Health (NIH)/National Institute on Aging (NIA) Accelerating Medicines Partnership – Alzheimer’s Disease (AMP-AD) program and have applied it to a variety of complex diseases from Alzheimer’s to cancer. The strategy takes into account genetic, epigenetic, transcriptomic, pathological, and clinical data from a large pool of tissue samples and identifies links between them.
“This multiscale network analysis approach is a powerful way to dissect the molecular mechanisms of complex diseases like Alzheimer’s,” said Suzana Petanceska, PhD, program director of the AMP-AD Target Discovery program at the NIA, which co-funded the study. “It is exciting to see that AMP-AD can provide new mechanistic insights to Parkinson’s disease that could lead to new therapeutic opportunities.”
Unfortunately, there are no gene expression data sets based on a sufficiently large number of informative brain samples from Parkinson’s patients for the powerful MGNA to be effective. Instead, the researchers combined data from eight different studies that included postmortem analyses of the substantia nigra–the part of the brain most affected by Parkinson’s disease. This gave the team a larger dataset from a total of 83 patients, which they then compared to 70 controls who did not have Parkinson’s.
Applying MGNA to the combined data set, the scientists identified a number of key regulators of the gene networks that had never before been associated with the disease.
Next, they teamed up with Zhenyu Yue, PhD, Professor of Neurology and Neuroscience at the Icahn School of Medicine and the Director of Basic and Translational Research in Movement Disorders, whose work is supported by NIH Udall Centers of Excellence for Parkinson’s Disease Research, to experimentally validate the findings in mice. They chose to test the effects of STMN2, a gene that the analysis identified as a key regulator of the Parkinson’s molecular network. The gene is normally expressed in neurons that produce dopamine, a neurotransmitter that is depleted in the substantia nigra of Parkinson’s patients.
To test its influence on Parkinson’s disease, Dr. Yue and his team knocked down the STMN2 gene in the substantia nigra of the mice. RNA sequencing showed that reduction of STMN2 led to upregulation of nine genes that had previously been associated with the disease. The mice developed Parkinson’s-like pathologies such as degeneration of dopaminergic neurons in the substantia nigra and an increase in the concentration of the toxic, modified α-synuclein protein, both of which are considered hallmarks of the disease. Additionally, the mice struggled with motor tasks such as maintaining balance on a rod, indicative of the disruption of their motor function control.
Despite the fact that the team was able to create a large enough sample size to apply the multiscale network analysis, the researchers emphasized that 83 patients is still a relatively small number and the results should be validated in larger studies. Still, “The work opens up a new avenue for studying the disease,” said Dr. Yue. “The new genes we identified suggest that new pathways should be considered as potential targets for drug development, particularly for idiopathic Parkinson’s cases.”
Materials provided by The Mount Sinai Hospital / Mount Sinai School of Medicine. Content may be edited for clarity, style, and length.